In re Theragenics Corp. Securities Litigation

205 F.R.D. 631, 2002 U.S. Dist. LEXIS 6708, 2002 WL 342654
CourtDistrict Court, N.D. Georgia
DecidedMarch 5, 2002
DocketNo. CIV.A.1:99-CV-141-TWT
StatusPublished
Cited by9 cases

This text of 205 F.R.D. 631 (In re Theragenics Corp. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Theragenics Corp. Securities Litigation, 205 F.R.D. 631, 2002 U.S. Dist. LEXIS 6708, 2002 WL 342654 (N.D. Ga. 2002).

Opinion

ORDER

THRASH, District Judge.

This is a securities fraud action. It is before the Court on Defendants’ Motion to Compel Plaintiffs to Answer Interrogatories [Doc. 49]. For the reasons set forth below the Court grants the Defendants’ Motion to Compel.

J. BACKGROUND

Plaintiffs allege in their Second Amended Complaint that Defendants defrauded the investing public by touting the success of Ther-agenics’ product TheraSeed® without disclosing circumstances that would adversely affect future demand for the product. This Court dismissed Plaintiffs’ initial consolidated complaint, holding that Plaintiffs failed to allege sufficient facts upon which their information and belief allegations were based. The Plaintiffs were given permission to file an amended complaint. On October 6, 2000, Defendants filed a Motion to Dismiss Plaintiffs’ Second Amended Complaint (“SAC”), arguing that the amendments Plaintiffs made to their original amended pleading still failed to satisfy the heightened pleading requirements of the Private Securities Litigation Reform Act of 1995 (“Reform Act”), 15 U.S.C.A. § 78u-4 (West 1997). This Court in its March 30, 2001 Order denied Defendants’ motion, holding, with respect to Plaintiffs’ “information and belief’ allegations, that the Reform Act’s “all facts” requirement “does not require that plaintiffs plead with particularity every single fact upon which their beliefs concerning false or misleading statements are based. Rather, plaintiffs need only plead with particularity sufficient facts to support those beliefs.” However, this Court added that the “all facts” requirement “gets a commitment from the plaintiffs as to the sources of their information and belief [633]*633that can be tested at the summary judgement stage of the litigation.” The Court also indicated that “[t]he additional information may be obtained through discovery, but is not required to be included in the Complaint.”

On August 6, 2001, Defendants served their First Interrogatories on Plaintiffs, requesting the names of the individuals upon whom Plaintiffs relied in making the allegations in the SAC. (Motion to Compel Plaintiffs to Answer Interrogatories, Ex. 1). Plaintiffs objected and refused to name anyone with knowledge of the facts underlying their claims, despite having specifically alleged the existence of such persons. (See Lead Plaintiff Robert L. Thomas, Jr.’s Objections and Responses to Defendants’ First interrogatories to Plaintiffs, Response to Interrogatory Nos. 2, 3, 5, and 13 (Motion, Ex. 2)). On October 15, 2001, Defendants’ counsel conferred by telephone with Plaintiffs’ counsel to address Plaintiffs’ objections to Defendants’ Interrogatories. After the telephone conference, Plaintiffs by letter provided the names of fifty-four Amersham and Indigo employees whom Plaintiffs contend have knowledge of the facts underlying Plaintiffs’ claims. (See Letters from Salvatore J. Graziano to M. Robert Thornton, dated October 16 and October 17, 2001 (Motion Exs. 3 and 4)). This information was responsive to Defendants’ Interrogatory No. 13, which requested the names, addresses, and phone numbers of persons other than Theragenics employees whom Plaintiffs believe have knowledge of the facts and circumstances of Plaintiffs’ claims.

Defendants’ Interrogatory No. 2 called upon the Plaintiffs to “[ijdentify all former employees of Indigo Medical, Inc. and Am-ersham with whom you or your representatives communicated, as alleged in the preamble paragraph of the Second Amended Complaint, in investigating the allegations of Plaintiffs’ initial complaints, First Amended Complaint, or Second Amended Complaint.” Plaintiffs, however, refused to identify the persons interviewed as alleged in the SAC and as requested in Interrogatory No. 2. (Motion Ex. 3). Plaintiffs also refused to respond to Defendants’ request in Interrogatory No. 3 which called upon Plaintiffs to “[ijdentify all medical doctors who ‘were more comfortable using Iodine 125 to treat cancer’ as you allege in paragraph 20 of the Second Amended Complaint.” Finally, Plaintiffs refused to answer Interrogatory No. 5 which called upon Plaintiffs to “[ijden-tify the ‘senior supplier management employee’ at Indigo who provided information concerning what was ‘common knowledge’ at Indigo as alleged in paragraph 25 of the Second Amended Complaint.” In this motion, Defendants request that the Court intervene and order Plaintiffs to respond to Interrogatories No. 2, 3, and 5 as written.

II. DISCUSSION

A. Work Product Doctrine

The principles underlying the work product doctrine and Rule 26(b)(3) of the Federal Rules of Civil Procedure were set forth by the Supreme Court in Hickman v. Taylor, 329 U.S. 495, 67 S.Ct. 385, 91 L.Ed. 451 (1947).1 There, the Supreme Court recognized that “not even the most liberal discovery theories can justify unwarranted inquiries into files and mental impressions of an attorney.” Hickman v. Taylor, 329 U.S. 495, 510, 67 S.Ct. 385, 91 L.Ed. 451 (1947). The Court, in disallowing discovery of witness statements or notes of interviews conducted by counsel, set forth the underlying purpose of protecting an attorney’s trial preparation materials, stating that “it is essential that a lawyer work with a certain degree of privacy” and that proper preparation of a client’s case demands that he assemble information, decide what he considers to be relevant, prepare his legal theories and plan his strategy without needless interference. Id. at 511, 67 S.Ct. 385. In Hickman, the Supreme Court also made clear that the work product doctrine does not protect against the discovery of relevant non-privileged facts, whether or not they are contained in protected docu[634]*634ments or were learned by an attorney. Id. at 501, 507, 67 S.Ct. 385.

The work product doctrine was partially codified in 1970 in Rule 26(b)(3) of the Federal Rules of Civil Procedure. The Rule explicitly protects from discovery documents and things prepared by a party or his representative in anticipation of litigation or in preparation for trial. Production of those documents can be compelled only where the seeking party demonstrates a “substantial need” for the materials and an inability to obtain the substantial equivalent of the desired information by other means. Rule 23(b)(3) contemplates, however, that even when a party can justify the production of work product documents, the court must protect against the disclosure of the opinions, mental processes and legal theories of an attorney.

B. Interrogatory Nos. 2 and 5

Numerous courts since Hickman v. Taylor, 329 U.S. 495, 511, 67 S.Ct. 385, 91 L.Ed. 451(1947), have recognized that names and addresses of witnesses interviewed by counsel who have knowledge of the facts alleged in the complaint are not protected from disclosure by the work product doctrine.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
205 F.R.D. 631, 2002 U.S. Dist. LEXIS 6708, 2002 WL 342654, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-theragenics-corp-securities-litigation-gand-2002.